Ribavirin
brand names: Copegus , Rebetol , Ribasphere, Vilona and Virazole, is an anti-viral drug indicated for severe RSV infection (individually), hepatitis C infection (used in conjunction with peginterferon alfa-2b or peginterferon alfa-2a) and other viral infections.
Most common Ribavirin side effects
- Fatigue - (10,388 reports)
- Anaemia - (9,121 reports)
- Nausea - (8,019 reports)
- Rashes - (7,294 reports)
- Headache - (4,795 reports)
- Thrombocytopenia - (4,607 reports)
- Itching - (4,580 reports)
- White blood cell count decreased - (4,350 reports)
- Nausea and vomiting - (4,119 reports)
- Weakness - (4,117 reports)
Ribavirin is a prodrug, which when metabolised resembles purine RNA nucleotides. In this form it interferes with RNA metabolism required for viral replication. How it exactly affects viral replication is unknown. The primary observed serious adverse side effect of ribavirin is hemolytic anemia, which may worsen preexisting cardiac disease. The mechanism for this effect is due to ribavarin's buildup inside erythrocytes. Oxidative damage to erythrocyte cell membrane is usually inhibited by glutathione; however, with reduced ATP levels caused by ribavirin, glutathione levels are impaired, permitting oxidative erythrocyte cell lysis. The gradual loss of erythrocytes leads to anemia. Ribavirin is also a teratogen in some animals species and thus poses a theoretical reproductive risk in humans, remaining a hazard as long as the drug is present, which can be as long as 6 months after a course of the drug has ended.
On Jan, 23, 2017 65,554 people reported to have side effects when taking Ribavirin. Among them, 283 people (0.43%) have Hallucination
On Jan, 31, 2017 65,554 people reported to have side effects when taking Ribavirin. Among them, 81 people (0.12%) have Hallucination, Auditory
On Jan, 31, 2017 65,554 people reported to have side effects when taking Ribavirin. Among them, 8 people (0.01%) have Hallucination, Olfactory
On Jan, 10, 2017 14,211 people reported to have side effects when taking Copegus. Among them, 81 people (0.57%) have Hallucination
On Jan, 31, 2017 14,211 people reported to have side effects when taking Copegus. Among them, 30 people (0.21%) have Hallucination, Auditory
On Jan, 16, 2017 24,304 people reported to have side effects when taking Rebetol. Among them, 71 people (0.29%) have Hallucination
On Jan, 15, 2017 24,304 people reported to have side effects when taking Rebetol. Among them, 37 people (0.15%) have Hallucination, Auditory
On Jan, 31, 2017 24,304 people reported to have side effects when taking Rebetol. Among them, 1 person (0.0%) has Hallucination, Tactile
On Jan, 31, 2017 8,837 people reported to have side effects when taking Ribasphere. among them, 43 people (0.49%) have Hallucination
On Jan, 31, 2017 8,837 people reported to have side effects when taking Ribasphere. Among them, 20 people (0.23%) have Hallucination, Auditory
Time on Ribavirin when people have Hallucination :
| |
< 1 month |
1 - 6 months |
6 - 12 months |
1 - 2 years |
2 - 5 years |
5 - 10 years |
10+ years |
| Hallucination |
16.88% |
59.74% |
22.08% |
0.00% |
1.30% |
0.00% |
0.00% |
Gender of people who have Hallucination when taking Ribavirin :
| |
Female |
Male |
| Hallucination |
52.60% |
47.40% |
Age of people who have Hallucination when taking Ribavirin :
| |
0-1 |
2-9 |
10-19 |
20-29 |
30-39 |
40-49 |
50-59 |
60+ |
| Hallucination |
0.00% |
0.00% |
0.00% |
3.73% |
14.29% |
31.06% |
43.48% |
7.45% |
On Mar, 20, 2015: 23,521 people reported to have side effects when taking Ribavirin. Among them, 344 people (1.46%) have Death.
Time on Ribavirin when people have Death :
| |
< 1 month |
1 - 6 months |
6 - 12 months |
1 - 2 years |
2 - 5 years |
5 - 10 years |
10+ years |
| Death |
29.13% |
48.54% |
19.42% |
2.91% |
0.00% |
0.00% |
0.00% |
Gender of people who have Death when taking Ribavirin :
| |
Female |
Male |
| Death |
27.66% |
72.34% |
Age of people who have Death when taking Ribavirin :
| |
0-1 |
2-9 |
10-19 |
20-29 |
30-39 |
40-49 |
50-59 |
60+ |
| Death |
0.39% |
0.79% |
0.79% |
1.97% |
3.15% |
19.69% |
55.51% |
17.72% |
